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ABSTRACT
Background Myotonic dystrophy (MD1) is a hereditary
autosomal dominant disease with variable penetrance.
Cardiac conduction disturbances are frequent and may
be responsible for sudden death, but its progression was
heretofore unknown.
Aims The aim of the study was to analyse the natural
history of infrahissian conduction time in patients with
a normal ﬁrst electrophysiological test, and to identify
the predictive value of the clinical and ECG factors
accompanying an alteration of infrahissian conduction.
Methods Among 127 consecutive screened MD
patients, 25 were enrolled and underwent a second
electrophysiological testing. The second
electrophysiological test was carried out on patients
showing new symptoms, new atrioventricular conduction
disturbances on ECG, or signiﬁcant modiﬁcations of
signal-averaged (SA)-ECG, and on asymptomatic
patients with a follow-up of at least 60 months since the
ﬁrst electrophysiological test.
Results Among the 25 patients, four had new clinical
symptoms, four others developed new atrioventricular
conduction abnormalities on ECG and six had signiﬁcant
modiﬁcations of the SA-ECG. The mean His-ventricle
(HV) interval increased signiﬁcantly between the two
electrophysiological studies (initial HV interval
52.1 ms61.6 ms, ﬁnal HV interval 61.4 ms62.2 ms,
p<0.005), with a mean increase of 1.2 ms/year. The ﬁve
patients with HV interval of 70 ms or greater were
implanted with a prophylactic dual-chamber pacemaker.
Modiﬁcations of resting ECG and SA-ECG were strongly
associated with HV interval prolongation.
Conclusion In patients with a normal initial
electrophysiological study, modiﬁcations on the resting
ECG and/or SA-ECG, on annual check-up, were
associated with an alteration of infrahissian conduction.
Myotonic dystrophy (MD1), the most frequent
adult form of muscular dystrophy, is a hereditary
autosomal dominant disease with variable
penetrance that occurs in one to 10 persons out of
100000.
1 It is caused by a mutation on the long
arm of chromosome 19 in the form of an unstable
expansion of cytosine-thymine-guanine (CTG)
repeats in the untranslated region of the gene for
myotonin protein kinase.
2 MD1 leads to multiple
systemic complications, essentially related to
muscular weakness, respiratory failure, cardiac
arrhythmias and cardiac conduction disturbances.
In the MD population, the age of death is
lower than in the general population,
3e5 and the
frequency of sudden death is higher.
3e11 The 2002
study by Lazarus et al
12 demonstrated that a pace-
maker should be implanted in patients with MD if
their His-ventricle (HV) interval is 70 ms or greater,
even if they are asymptomatic, in order to protect
them from the clinical consequences of profound
bradycardia and to facilitate the diagnosis and
management of frequent paroxysmal tachyar-
rhythmias. A high incidence of complete atrioven-
tricular block (AVB) was recorded on memory
pacemaker in MD patients with a HV interval of
70 ms or greater implanted with a prophylactic
pacemaker.
12 13
Moreover, Laurent et al
13 observed a very low
incidence rate of sudden death in MD patients (0.2/
100 patient-years) selected to receive a prophylactic
pacemaker on the basis of HV interval duration.
The beneﬁt of prophylactic pacemaker implanta-
tion was also conﬁrmed in MD patients estimated
to be at high risk of sudden death in accordance
with Groh’s ECG factors.
51 3These previous results
are a powerful argument in favour of the usefulness
of electrophysiological testing in MD patients to
select the candidates for prophylactic pacemaker
implantation. However, infrahissian conduction is
not stable over time and tends to increase in MD
patients.
14 So one unresolved question is when
should the electrophysiological testing be repeated
in MD patients without a pacemaker. In our study
of a large population of monitored MD patients, we
analysed the natural history of infrahissian
conduction time and tested the predictive value of
the clinical, resting ECG, and signal-averaged (SA)-
ECG parameters of an alteration of infrahissian
conduction (prolongation of HV interval $70 ms).
METHODS
Population
All patients with MD1 conﬁrmed by genetic and
electromyographic study and treated by our
university institution’s multidisciplinary team for
the care of patients with neuromuscular disease
were recruited. Some of the patients included in the
present study have already been described in
previous studies.
13 15 New patients with MD1 who
were presented to the multidisciplinary team due
to recent disease diagnosis, or new symptoms or
new resting ECG abnormalities were also include in
this study. Clinical data were prospectively
collected and evaluated every year. The annual
check-up consisted of a physical examination by
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Heart rhythm disordersa cardiologist, a neurologist and a chest specialist. Functional
status, supplemented by the recording of resting ECG, SA-ECG
and pulmonary capacity, was monitored once a year. The MD
patients without pacemakers and who had previously under-
gone an electrophysiological study were selected for our study. A
second electrophysiological study was proposed to the patients
in the event of new symptoms (unexplained syncope or
presyncope, palpitations), new atrioventricular conduction
disturbances on annual resting ECG, signiﬁcant modiﬁcations of
SA-ECG with respect to the previous study,
15 and atrial
arrhythmias justifying anti-arrhythmic drugs, or in asymptom-
atic patients with a follow-up of at least 60 months. This time
interval between the ﬁrst and second electrophysiological tests
in asymptomatic patients was chosen from the study of Prys-
towsky et al,
14 who reported a 5 ms prolongation of the HV
interval over a 3-year period in several patients, and from the
study of Laurent et al,
13 who reported a complete AVB in one
patient with a normal HV interval 5 years earlier. Therefore,
60 months after the ﬁrst electrophysiological test the HV
interval would be prolonged by 10 ms and could exceed 70 ms.
Once identiﬁed, MD patients with these criteria underwent
electrophysiological testing after informed consent was obtained
and signed. Patients who were initially studied less than
60 months without new symptoms, or without signiﬁcant
changes in resting ECG or SA-ECG were not considered for
a new electrophysiological study.
Electrophysiological testing
The electrophysiological testing was performed using standard
techniques with two quadripolar catheters introduced into the
femoral vein and worked up into the bundle of His region of the
right atrium. Several variables were measured during the elec-
trophysiological study: atrial-His (AH) interval (ms), HV
interval (ms), atrioventricular Wenckebach points (beats/min)
during right atrial stimulation at increasing rate, sinus node
recovery time (ms). The criterion for proposing a prophylactic
pacemaker implantation was a HV interval of 70 ms or greater.
Programmed right ventricular stimulation was not performed.
Signal-averaged ECG
Recordings were performed using Simson’s method with an
ART recorder (model 120; Arrhythmia Research Technology,
Austin, Texas, USA). The ECG was recorded with standard
bipolar orthogonal X, Y, Z leads. Signals were ampliﬁed,
averaged and ﬁltered with bidirectional ﬁltered frequencies of
40e250 Hz. As previously reported,
15 the association of QRSD
(total QRS duration) of 100 ms or greater and LAS40 (duration
of low amplitude signal<40mV) of 36 ms or greater on SA-ECG
contributes to the identiﬁcation of MD patients with
a prolonged HV interval. Five patients reported in the previous
study in 1999 were also included in the present study. These
criteria are not those commonly used to identify patients at risk
of sustained ventricular tachycardia post-myocardial infarction,
but in MD they are linked to infrahisian conduction alteration
and not to ventricular arrhythmia substrate.
16
Study endpoints
The primary endpoint was to evaluate the evolution over time
of the infrahissian conduction time in adult MD patients. The
second endpoint was to deﬁne the predictive clinical and elec-
trocardiographic parameters of a severe alteration in infrahissian
conduction time that would justify a repetition of electrophys-
iological testing in MD patients with a view to proposing the
prophylactic implantation of a pacemaker.
Statistical analysis
Data were reported as the mean6SD. Baseline characteristics in
patients with and without prolonged HV interval were
compared using univariate analysis and the Fisher’s exact test
for qualitative parameters and the ManneWhitney test for
quantitative parameters. The correlation between the variation
of HV interval (HV2eHV1) and the size of the mutation was
analysed using the linear regression method. A p value less than
0.05 was considered signiﬁcant.
RESULTS
Starting in 1994, 70 of 127 consecutively screened patients with
MD1 were not initially implanted with a pacemaker. All
patients were classiﬁed as having an adult-onset form of MD.
The clinical characteristics of these 70 patients are summarised
in table 1. Twenty-ﬁve of these 70 patients were enrolled and
underwent a second electrophysiological testing. Figure 1 shows
the enrolment of the study population. No signiﬁcant differ-
ences were observed between the initial clinical characteristics of
the 25 patients enrolled in the present study (age, sex, Brooke
score, Epworth score, resting ECG, right and left ventricular
ejection fraction, CTG ampliﬁcation) and the 45 patients who
did not initially receive a pacemaker (table 1) and who were not
enrolled in the present study for different reasons set out in
ﬁgure 1. The upgraded clinical characteristics of the 25 patients
undergoing a second electrophysiological study are summarised
in table 2.
Neurological functional status was evaluated by the Brooke
score.
17 The severity of muscular weakness was scored at the
level of arms (range from 1 to 6) and legs (range from 1 to 10). It
ranged from 2 to 11 in our patients. Four patients had a score of
5 or greater. Only two patients were conﬁned to a wheelchair.
No patient was under permanent mechanical respirator at the
time of the second electrophysiological testing. The excessive
daytime sleepiness was evaluated by the Epworth sleepiness
scale with eight items.
18 Each item accounts for 0e3 points.
Sleep apnoea syndrome was diagnosed with standard poly-
somnographic studies in 11 patients. This sleep apnoea
syndrome was treated by nocturnal non-invasive positive pres-
sure ventilation in eight patients. Eleven patients had cataracts
and 12 had alopecia. The mean value of creatine phosphokinase
Table 1 Initial mean characteristics of the MD patients without
a pacemaker
Group 1 (n[70)
mean±SD
Group 2 (n[45)
mean±SD
Group 3 (n[25)
mean±SD
Age (years) 40615 41.5615 37.2614
Women n, (%) 28 (40) 21 (46) 7 (28)
Brooke score 3.362.3 3.462.6 3.461.7
Abnormal ECG 20 (28.5) 14 (31.1) 8 (32)
Spontaneous AF, n (%) 8 (11) 6 (13.3) 2 (8)
Spontaneous NSVT, n 1 1 0
LVEF (%) 59.4610 57.2610.7 62.369.1
LVEF <50%, n 9 7 2
RVEF (%) 44.2610 43.2611 46.268
LVEDD (mm) 46.564 47.565 45.665
CTG repeat length Kb 2.161.5 261.6 2.461.3
Group 1 all patients without pacemaker in our global myotonic dystrophy (MD) population;
group 2 patients excluded from the present study for different reasons explained in ﬁgure 1;
group 3 patients enrolled in the study who underwent two electrophysiological studies.
Group 1 versus group 2 versus group 3 not signiﬁcant differences for all parameters.
AF, atrial ﬁbrillation; CTG, cytosine-thymine-guanine; LVEDD, left ventricular end-diastolic
dimension; LVEF, left ventricular ejection fraction; NSVT, non sustained ventricular
tachycardia; RVEF, right ventricular ejection fraction.
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Heart rhythm disorderswas 2056165 UI (from 64 to 712, normal value <145 UI) and
ﬁve patients had signiﬁcant vesicular lithiasis.
Left ventricular ejection fraction was normal (>50%) in 21
patients (84%) and slightly altered in four patients (ranging
from 45% to 50%). Right ventricular radionuclide function was
available for 13 patients and was normal in four of them (>45%)
and slightly altered in nine others (ranging from 30% to 45%).
ECG patterns
Initially, 17 patients (68%) showed normal conduction intervals
on their ﬁrst ECG. Among the remaining patients, four had left
anterior block, two had isolated 18 AVB, one had 18 AVB asso-
ciated with right bundle branch block, and one had both right
bundle branch block and left anterior block. At the time of the
second electrophysiological test only four patients had devel-
oped new atrioventricular conduction abnormalities (table 2).
One patient presented with a symptomatic bradytachycardia
syndrome. The evolution of ECG is summarised in table 3.
Five patients had paroxysmal atrial arrhythmias. Atrial ﬁbril-
lation was treated by amiodarone (n¼1) which does not severely
depress the infrahisian conduction.
19 Atrial ﬂutter was treated
by cavo-tricuspid isthmus ablation (n¼1). Three patients were
not treated by anti-arrhythmic drugs because the atrial
arrhythmias were not symptomatic.
On 24 h ECG, paroxysmal AVB of second and third degree
was not observed.
Signal-averaged ECG
Modiﬁcations of SA-ECG reaching the signiﬁcant cut-off deﬁned
by QRSD of 100 ms or greater and LAS of 36 ms
15 or greater
were observed in six patients.
In one patient, SA-ECG was invalid because of the level
of noise, and in another it could not be performed due to
a technical problem. The mean values of SA-ECG parameters
were: QRSD 105610.8 ms, under 40 36.5612 ms, HFRMSA
(root mean square voltage of signals in the last 40 ms of the QRS
complexes) 30.3624.7 mV.
Electrophysiological testing
The mean age at the second electrophysiological test was
44.4613.6 years. The mean interval between the ﬁrst and the
second electrophysiological test was 90.8636 months
(minimum 24 months, maximum 144 months). Four patients
were given the second electrophysiological test because they
developed new symptoms, four others on account of modiﬁca-
tions in resting ECG, one other for a bradytachycardia
syndrome, only three for abnormal SA-ECG, and 13 patients
merely because the follow-up exceeded 60 months. In asymp-
tomatic patients with no ECG or SA-ECG modiﬁcation, the
mean interval between the ﬁrst and the second electrophysio-
logical test tended to be longer than in other patients (101634
months versus 81629 months, NS). At the second electro-
physiological test the HV interval was 70 ms or greater in
ﬁve cases (20%). The mean value of the HV interval increased
signiﬁcantly between the two electrophysiological tests (ﬁgure 2
and table 3). The Wenckebach point was 154629 beats/min. No
infrahissian block was provoked by increasing atrial stimulation.
Sinus node function was abnormal in one patient. The mean
corrected sinus node recovery time was 2976246 ms. Five
patients with HV interval of 70 ms or greater were implanted
with a prophylactic dual-chamber pacemaker. The patient with
bradytachycardia syndrome was given an oral anti-arrhythmic
agent, amiodarone 200 mg/day and a pacemaker.
Characteristics of patients with abnormal HV interval
The ﬁve patients with a HV interval of 70 ms or greater at the
second electrophysiological test showed a modiﬁcation in their
resting ECG over time (n¼4) or signiﬁcant modiﬁcations in the
SA-ECG (n¼3) (table 3 and ﬁgure 2). One of the MD patients
with stable resting ECG, despite a prolonged HV interval,
showed signiﬁcant lengthening of SA-ECG parameters (patient
24 in table 3). QRSD and under 40 tended to be longer in the
prolonged HV interval group than in normal HV interval group
(QRDS 109.866 vs 103.6611 ms, under 40 42.4618 vs
3469.6 ms).The mean duration of the follow-up was not
signiﬁcantly different between the group of patients with a HV
interval of 70 ms or greater at the second electrophysiological
test and those without a HV interval of 70 ms or greater at the
second electrophysiological test (80646 vs 93.5634 months,
NS). None of the clinical characteristics were signiﬁcantly
different between the two groups in terms of age, severity of
muscular weakness and frequency of sleep apnoea syndrome;
nor was the size of the mutation signiﬁcantly different in those
patients (2.561.1 vs 2.261.9 kb, NS). No correlation was
established between the variation in the HVinterval and the size
of the mutation (r
2¼0.03, NS).
Figure 1 Myotonic dystrophy patient enrolment. Among 70 patients
without pacemakers, 25 underwent a second electrophysiological test.
AVB, atrioventricular block; EP, electrophysiological test; HV, His-
ventricle; SA-ECG, signal-averaged ECG.
Table 2 Upgraded clinical characteristics of the patients who
underwent a second electrophysiological test
Patients (n[25)
mean±SD (range)
Age (years) 44613.6 (24e73)
Women, n (%) 7 (28)
Brooke score 3.462.5 (2e11)
Epworth score 6.864.5 (0e17)
Abnormal ECG, n (%) 10 (40)
Spontaneous atrial arrhythmias, n (%) 5 (20)
Spontaneous NSVT, n (%) 0
LVEF (%) 5869 (45e75)
LVEF <50% n 4
RVEF (%) 4066 (30e54)
LVEDD (mm) 4664 (37e52)
CTG repeat length Kb 2.461.3 (0.5e5.5)
CTG, cytosine-thymine-guanine; LEVD; LVEDD, left ventricular end-diastolic dimension;
LVEF, left ventricular ejection fraction; NSVT, non sustained ventricular tachycardia; RVEF,
right ventricular ejection fraction.
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Heart rhythm disordersPredictive value of resting ECG and SA-ECG
Resting ECG is very useful for the identiﬁcation of patients with
an alteration of infrahissian conduction. Of the ﬁve patients
with a new prolongation of the HV interval, four showed
signiﬁcant modiﬁcation in their resting ECG. Only one patient
without modiﬁcation of ECG had a prolonged HV interval
(sensitivity 80%, speciﬁcity 99%).
SA-ECG was signiﬁcantly modiﬁed in six patients but was
associated with prolonged interval in only three patients
(sensitivity 100%, speciﬁcity 50%).
The combination of modiﬁcations of resting ECG and
SA-ECG identiﬁed all patients with prolonged HV interval
(sensitivity 100% and speciﬁcity 75%).
DISCUSSION
This study, for the ﬁrst time, shows the evolution of the resting
ECG and SA-ECG characteristics and of the HV interval in
non-selected adult MD patients monitored every year in the
same reference centre. Some signiﬁcant modiﬁcations of resting
ECG were observed in four patients and abnormal SA-ECG in six
patients, and were strongly associated with an HV interval
prolongation. The HV interval increase was not linked to any
new symptoms such as syncope or palpitations, or to the
duration of the follow-up.
Nguyen et al
20 reported that abnormalities of the cardiac
conduction system were commonly observed in MD due to
frequent fatty inﬁltration and ﬁbrosis of the His bundle. The
electrophysiological consequences of these histopathological
lesions were frequent infrahissian conduction disturbances on
electrophysiological testing (prolonged HV interval) and a high
risk of complete AVB in MD patients.
12 13 21 In animal models
for dystrophy myotonic protein kinase (DMPK) reduction the
same histopathological lesions and His Purkinje system alter-
ations were reported.
22 A time-dependent degenerative process
has been suggested by Groh et al,
23 who observed a correlation
between age and ECG abnormalities, and by Prystowsky et al,
14
who in serial electrophysiological studies demonstrated the
progression of infrahissian conduction time in a small number
(n¼9) of non-consecutive MD patients. However, in the large
study by Laurent et al,
13 including 51 MD patients with
Table 3 Electrophysiological characteristics of patients who underwent a second electrophysiological study
Patients ECG 1 HV 1 ms
Indication 2nd
electrophysiological study
Time interval between
EP in months ECG 2 SA-ECG2 HV 2 ms Pacemaker
1 Normal 45 Follow-up 75 Normal Negative 50 No
2 Normal 55 Follow-up 136 Normal Negative 55 No
3 Normal 35 CP and palpitations 48 Normal Negative 50 No
4 LAB 50 Follow-up 58 LAB Positive 60 No
5 AVB 1 + RBBB 58 Presyncope 48 AVB 1 + RBBB Negative 65 No
6 AVB 1 60 ECG modiﬁcation 24 AVB 1 Negative 80 Yes
7 Normal 50 ECG modiﬁcation 108 LAB Positive 70 Yes
8 Normal 40 Follow-up 118 Normal Positive 45 No
9 Normal 55 Follow-up 78 Normal Negative 60 No
10 Normal 55 Follow-up 132 Normal Negative 55 No
11 Normal 30 Syncope 50 Normal Negative 50 No
12 Normal 50 Follow-up 144 Normal Negative 60 No
13 Normal 50 ECG modiﬁcation 132 LBBB y 90 Yes
14 LAB 55 Follow-up 132 LAB Negative 50 No
15 Normal 60 Follow-up 96 Normal Negative 60 No
16 LAB + RBBB 60 ECG modiﬁcation 96 AVB 1 + LAB + RBBB Positive 80 Yes
17 AVB 1 50 Follow-up 72 AVB 1 e 50 No
18 LAB 50 Follow-up 96 LAB Negative 60 No
19 LAB 55 Follow-up 142 LAB Negative 65 No
20 Normal 50 Bradytachycardia 72 Normal Negative 55 Yes*
21 Normal 60 SA-ECG + 43 Normal Negative 60 No
22 Normal 50 Follow-up 120 Normal Negative 65 No
23 Normal 60 Syncope, SA-ECG + 90 Normal Positive 60 No
24 Normal 60 SA-ECG + 40 Normal Positive 80 Yes
25 Normal 60 Follow-up 120 Normal Negative 60 No
Signal-averaged (SA)-ECG was regarded as the presence of QRSD of 100 ms or greater and LAS40 of 36 ms or greater.
15
*Pacemaker implanted for brady-tachycardia syndrome.
yInvalid because of noise.
AVB 1, atrioventricular block 1; CP, chest pain; EP, electrophysiological testing; HV, His-ventricle; LAB, left anterior block; LBBBG, left bundle branch block, RBBB, right bundle branch block.
Figure 2 Evolution of His-ventricle (HV) interval (ms) in myotonic
dystrophy patients. Full black square: individual HV interval at the ﬁrst
electrophysiological study (HV1) and at the second electrophysiological
study (HV2) Full black circles: mean value of HV interval6ES (p<0.001).
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Heart rhythm disordersa normal HV interval of less than 70 ms followed up during
57636 months, only one patient developed a complete AVB,
52 months after the initial electrophysiological testing, whereas
19 of 49 patients with HV interval of 70 ms or greater developed
38 AVB. These results suggest two categories of adult MD
patients: one characterised by early infrahissian conduction
disturbances (HV interval $70 ms) frequently risking complete
AVB, and a second category of adult MD patients who may
exhibit a very slow progression of infrahissian conduction time.
This hypothesis is consistent with our results, which through
serial electrophysiological testing demonstrated a progression of
HV interval in only ﬁve of 25 patients during a prolonged period
of 90 months as opposed to Prystowsky et al,
14 who reported an
aggravation of HV interval in seven of nine selected patients
during a short 3-year period. This difference can be explained by
the high rate of abnormal resting ECG (7/9) and prolonged HV
interval (3/9) at the initial evaluation in the Prystowsky study.
14
Second, the high prevalence of complete AVB documented in
memory pacemaker in MD patients with an early HVinterval of
70 ms or greater points to a severe evolution of the infrahissian
conduction time in this subgroup of patients.
12 13 This hetero-
geneity of MD patients in terms of infrahissian characteristics is
compatible with the heterogeneity of the size of the mutation in
the different organs (somatic mosaicism), which is not exactly
the same for leucocytes. No correlation has been established
between respiratory insufﬁciency, weakness, or cardiac disease,
probably because the effect of the non-translated CTG repeat
expansion is not unique but multiple
24 and is not uniform from
one patient to another.
A second major ﬁnding of our study is the strong relationship
between the evolution of cardiac conduction disturbances on
resting ECG and the increase in the HV interval in a serial study.
No correlation between resting ECG and HV interval or histo-
pathological lesions
12 14 15 20 has been reported in the literature,
but the previous studies did not integrate the dynamism of the
atrioventricular conduction parameters in their analysis. In our
study patients with a signiﬁcant increase in the HV interval
corresponded approximately to those with a signiﬁcant
progression of cardiac conduction abnormalities on resting ECG.
Mörner et al
25 pointed out the importance of analysing the
progression of the atrioventricular conduction disturbances on
ECG. A progressive increase in PR interval and QRS duration on
resting ECG has been demonstrated as being statistically asso-
ciated with higher mortality in MD patients.
10 25 Groh et al
5
showed in a large population of MD patients that the resting
ECG was a crucial key in deﬁning those patients at high risk of
sudden death. In the subgroup of patients at high risk of
sudden death in accordance with the Groh criteria, Laurent
et al
13 showed that the implantation of a prophylactic pace-
maker in the presence of a prolonged HV interval decreased the
incidence of sudden death. Therefore, the evaluation of the risk
of sudden death should be re-checked by ECG every year.
Ventricular arrhythmias are the second mechanism evoked to
explain sudden death but the method of identifying MD
patients at risk is unknown. Ventricular arrhythmias induced
during electrophysiological study do not predict spontaneous
ventricular arrhythmias.
16 We can only suggest discussing the
implantation of an implantable cardioverter deﬁbrillator instead
of a pacemaker in MD patients with prolonged HV interval and
depressed left ventricular ejection fraction below 30%.
26
Breton and Mathieu
11 proposed integrating the analysis of QT
interval on resting ECG to identify MD patients at risk of
sudden death or pacemaker implantation. In presence of a QT
interval longer than 450 ms the age-adjusted RR was 3.
However, rigorous analysis of the QT interval remains a major
problem.
27 An automatic analysis and a dynamic analysis on
24 h ECG with the help of new software could be interesting to
limit the variability of the QT interval measurement.
SA-ECG is a useful tool in evaluating the infrahissian
conduction characteristics of MD patients.
15 Babuty et al
15
demonstrated that an association of QRSD of 100 ms or greater
and LAS of 36 ms or greater selects patients with a prolonged
HV interval of 70 ms or greater with high sensitivity (80%) and
speciﬁcity (83.3%). In the present study signiﬁcant changes in
the SA-ECG correlate with prolonged HV interval in three of six
patients. The combination of resting ECG and SA-ECG appears
to be the best method of identifying patients showing an
alteration over time of the infrahissian conduction time, with
excellent sensitivity (100%) and acceptable speciﬁcity (75%).
However, the usefulness of SA-ECG to identify MD patients
with prolonged infrahisian conduction has not been validated by
an another group.
Limitations of the study
The fact that not all the patients without a pacemaker were
systematically re-investigated could introduce a bias in this
study. However, we have veriﬁed that the clinical characteristics
of the 25 patients included in the study did not differ statisti-
cally from the 45 patients not re-investigated for different
reasons (table 1 and ﬁgure 1).
Some patients could have a normal ECG and prolonged HV
interval due to a short AH interval.
12 These patients, however,
can be identiﬁed by the SA-ECG, which, as previously
mentioned in the discussion, accurately reveals infrahissian
conduction abnormalities.
For the moment there is no randomised, controlled study in
the literature clearly indicating that preventive pacemaker
implantation in patients with a HV interval greater than 70 ms
decreases mortality and morbidity in MD. Only observational
and non-controlled studies suggest a real beneﬁt from the
prophylactic implantation of a pacemaker in the presence of
a prolonged HV interval of 70 ms or greater.
12 13
CONCLUSION ON CLINICAL IMPLICATIONS
The infrahissian conduction disturbances frequently observed in
adult MD patients justify the early identiﬁcation of patients
with a prolonged HV interval, who are at high risk of complete
AVB. This can be done by carrying out an early electrophysio-
logical study at the time of MD diagnosis. Prophylactic
implantation of a pacemaker should be proposed to patients
with a HV interval of 70 ms or greater. In patients with an
initially normal infrahissian conduction time on the electro-
physiological study, the risk of complete AVB is very low, and
a second electrophysiological study should be performed only in
the event of modiﬁcations in atrioventricular conduction ECG
parameters or SA-ECG in annual check-ups. In the future, it will
be important to conduct a controlled and randomised study in
order to demonstrate clearly the beneﬁts of prophylactic pace-
maker implantation in MD patients with a HVinterval of 70 ms
or greater.
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